Related Experiment Video
Updated: May 24, 2026
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
1Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.
Abstract:
Src is a nonreceptor tyrosine kinase essential for the activation of osteoclasts, the cells that degrade bone. Src also regulates normal cell functions, cancer cell growth and metastasis to organs, including bone where tumor cells induce bone destruction by osteoclasts. Src inhibitors prevent bone destruction and tumor cell growth in animal models of metastatic bone disease, and some are being investigated in clinical trials, particularly in patients with prostate cancer, which has high bone metastatic potential. Here, we review how Src regulates osteoclast formation, activation and survival and the results of preclinical and clinical trials of Src inhibitors, which show some promise in inhibiting the effects of tumor cells on the skeleton.
Insights
Src kinase is crucial for osteoclast activation and bone degradation. Src inhibitors show promise in preventing bone destruction and cancer growth in metastatic bone disease models.
Area of Science:
- Biochemistry
- Oncology
- Orthopedics
Background:
- Src is a nonreceptor tyrosine kinase vital for osteoclast function.
- Osteoclasts are key cells responsible for bone resorption.
- Src also plays a role in cancer progression and metastasis.
Purpose of the Study:
- To review the role of Src in osteoclast biology.
- To summarize the efficacy of Src inhibitors in preclinical and clinical settings for metastatic bone disease.
Main Methods:
- Literature review of Src's function in osteoclasts.
- Analysis of preclinical animal models of bone metastasis.
- Summary of clinical trial data for Src inhibitors.
Main Results:
- Src regulates osteoclast formation, activation, and survival.
- Src inhibitors demonstrated efficacy in preventing bone destruction in animal models.
- Clinical trials indicate potential therapeutic benefits for Src inhibitors.
Conclusions:
- Src is a critical regulator of bone remodeling and cancer-induced bone destruction.
- Src inhibitors represent a promising therapeutic strategy for managing metastatic bone disease, particularly in prostate cancer.
